TSXV - Delayed Quote CAD

NurExone Biologic Inc. (NRX.V)

0.5000 +0.0250 (+5.26%)

At close: November 6 at 3:49:26 PM EST

NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes

GlobeNewswire 8d ago

NRX.V
+5.26%
J90.F

NRXBF
NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth

GlobeNewswire 16d ago

NRX.V
+5.26%
J90.F

NRXBF
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results

GlobeNewswire 29d ago

NRX.V
+5.26%
J90.F

NRXBF
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update

GlobeNewswire 1mo ago

NRX.V
+5.26%
NRXBF

J90.SG
NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

GlobeNewswire 1mo ago

NRX.V
+5.26%
J90.MU

NRXBF
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications

GlobeNewswire 1mo ago

NRX.V
+5.26%
J90.SG

NRXBF
NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing

InvestorsHub 2mo ago

NRX.V
+5.26%
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results

GlobeNewswire 2mo ago

NRX.V
+5.26%
J90.F

NRXBF
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

GlobeNewswire 2mo ago

NRX.V
+5.26%
J90.F

NRX
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy

GlobeNewswire 2mo ago

NRX.V
+5.26%
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership

GlobeNewswire 2mo ago

NRX.V
+5.26%
NRXBF

J90.F
NurExone Announces Closing of Non-Brokered Private Placement

GlobeNewswire 4mo ago

NRX.V
+5.26%
NRX.NE

J90.F

U.S. markets closed

NurExone Biologic Inc. (NRX.V)

NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes

NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth

NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results

NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update

NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications

NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing

NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy

NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership

NurExone Announces Closing of Non-Brokered Private Placement